Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Nov;190(2):265-275.
doi: 10.1007/s10549-021-06367-5. Epub 2021 Sep 3.

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

Lori J Goldstein  1 , Mauro Mansutti  2 , Christelle Levy  3 , Jenny C Chang  4 , Stephanie Henry  5 , Isaura Fernandez-Perez  6 , Jana Prausovà  7 , Elzbieta Staroslawska  8 , Giuseppe Viale  9   10 , Beth Butler  11 , Susan McCanna  11 , Pier Adelchi Ruffini  11 , Max S Wicha  12 , Anne F Schott  12 ; fRida Trial Investigators
Collaborators, Affiliations
Clinical Trial

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

Lori J Goldstein et al. Breast Cancer Res Treat. 2021 Nov.

Abstract

Purpose: CXCR1, one of the receptors for CXCL8, has been identified as a druggable target on breast cancer cancer stem cells (CSC). Reparixin (R), an investigational oral inhibitor of CXCR1, was safely administered to metastatic breast cancer patients in combination with paclitaxel (P) and appeared to reduce CSC in a window-of-opportunity trial in operable breast cancer. The fRida trial (NCT02370238) evaluated the addition of R to weekly as first-line therapy for metastatic (m) TNBC.

Subjects and methods: Subjects with untreated mTNBC were randomized 1:1 to R or placebo days 1-21 in combination with weekly P 80 mg/m2 on days 1, 8, 15 of 28-day cycles. The primary endpoint was PFS by central review.

Results: 123 subjects were randomized (62 to R + P and 61 to placebo + P). PFS was not different between the 2 groups (median 5.5 and 5.6 months for R + P and placebo + P, respectively; HR 1.13, p = 0.5996). ALDH+ and CD24-/CD44+ CSC centrally evaluated by IHC were found in 16 and 34 of the 54 subjects who provided a metastatic tissue biopsy at study entry. Serious adverse events (21.3 and 20% of subjects) and grade ≥ 3 adverse reactions (ADR) (9.1 and 6.3% of all ADRs) occurred at similar frequency in both groups.

Conclusion: fRida is the first randomized, double-blind clinical trial of a CSC-targeting agent in combination with chemotherapy in breast cancer. The primary endpoint of prolonged PFS was not met.

Clinical trial registration/date of registration: NCT01861054/February 24, 2015.

Keywords: CXCR1; Cancer stem cells; Reparixin; TNBC.

PubMed Disclaimer

Conflict of interest statement

PAR, SMC, and BB are full-time employees of Dompé farmaceutici s.p.a. All other authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Patient disposition: Randomization, trial populations, and follow-up are shown, and so are the numbers of subjects who were receiving study treatment on the data cutoff date (February 20, 2019)
Fig. 2
Fig. 2
Progression-free survival in the ITT population: Kaplan–Meier estimates of PFS, according to the Response Evaluation Criteria in Solid Tumors, version 1.1, as assessed by the independent radiology review, among subjects in the ITT population. Stratified hazard ratios for disease progression or death are reported along with p values. Tick marks indicate censored data
Fig. 3
Fig. 3
Overall survival in the ITT population: Kaplan–Meier estimates of OS among subjects in the ITT population. Stratified hazard ratios for death are reported along with p values. Tick marks indicate censored data. 6 subjects (4 in reparixin + paclitaxel and 2 in placebo + paclitaxel) did not re-sign ICF to protocol amendment 2 or later and were censored at 1 year after the off treatment visit
See this image and copyright information in PMC

References

    1. Clarke MF. Clinical and therapeutic implications of cancer stem cells. N Engl J Med. 2019;380(23):2237–2245. doi: 10.1056/NEJMra1804280. - DOI - PubMed
    1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983–3988. doi: 10.1073/pnas.0530291100. - DOI - PMC - PubMed
    1. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Can Res. 2009;69(4):1302–1313. doi: 10.1158/0008-5472.can-08-2741. - DOI - PMC - PubMed
    1. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Investig. 2010;120(2):485–497. doi: 10.1172/jci39397. - DOI - PMC - PubMed
    1. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M, Stanford J, Cook RS, Arteaga CL. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Investig. 2013;123(3):1348–1358. doi: 10.1172/jci65416. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data